Survivors of childhood cancer face challenges from bone mineral density (BMD) deficits due to treatment exposures and other ...

When Anne Maldzinski underwent a blood stem-cell transplant to cure her cancer, the procedure triggered a life-threatening ...

The FDA has granted BTD to GSK’22, a B7-H3-targeted antibody-drug conjugate, for the treatment of adult patients with ...

Fred Hutch grew from a regional cancer center into a world-class biomedical research and clinical care institution known for ...

Childhood Cancer Society and Tour de Taverns worked with the Marco Island community to give a local girl with cancer a ...

Study finds dialysis patients taking denosumab have 36% higher risk for major cardiovascular events compared to those taking oral bisphosphonates.

Recruitment freezes in NHS scanning and cancer departments are risking patient care, the Royal College of Radiologists (RCR) ...

A Coralville mother is on a mission to raise awareness and funds for osteosarcoma research following the death of her ...

GSK plc (GSK, GSK.L) said that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for GSK5764227, its ...

The FDA bestows a Breakthrough Therapy designation to GSK's antibody-drug conjugate, GSK5764227, for treating relapsed or refractory osteosarcoma.

The system is based on novel technology that promises to simplify treatment and delivery and increase the number of patients ...

Oncologist Thomas C. Weiner misdiagnosed Anthony Olson with MDS in 2011. Olson is one of many patients who may have received unnecessary and harmful treatments after being misdiagnosed by Weiner.